N Reed - Rare and Uncommon Gynecological Cancers, 2011 - Springer Uterine sarcomas present a challenging group of tumours to manage, but the focus in this chapter will be on uterine leiomyosarcomas (LMS) [1]. Nevertheless, historically these tumours have been lumped together with carcino- sarcomas and are usually treated by Gynaecological ... Related articles - All 2 versions
[PDF] from banglajol.infoMM Hassan, M Ahmed, RA Bhuiyan… - Journal of Bangladesh …, 2011 - banglajol.info 1. Dr. Md. Mokerrom Hasan. BDS, BCS, FCPS(OMS), OSD DGHS, Deputed to Department Of Oral and Maxillofacial Surgery, Dhaka Dental College and Hospital. 2. Prof. Mohiuddin Ahmed. BDS, PhD(Japan), Head of the Department Of Oral and Maxillofacial Surgery, ... Related articles - All 3 versions
[CITATION] Histopathologic Prognostic Factors in Stage I Uterine Leiomyosarcoma of the Uterus: A Detailed Analysis of 27 Cases
WL Wang, R Soslow, M Hensley… - … American Journal of …, 2011 - journals.lww.com Uterine leiomyosarcomas (Ut-LMSs) are aggressive tumors with an overall poor prognosis (15% to 25% 5-year survival rate). However, patients with stage I Ut-LMSs are reported to have a relatively better outcome when compared with the overall group with a 5-year survival ... Related articles - All 3 versions
[HTML] from nih.govS Dhingra, ME Rodriguez, Q Shen… - … Journal of Clinical …, 2011 - ncbi.nlm.nih.gov The mammalian target of rapamycin (mTOR) is centrally involved in growth, survival and metabolism. In cancer, mTOR is frequently hyperactivated and is a clinically validated target for therapy and drug development. Biologically, mTOR acts as the catalytic subunit of two ... Cited by 1 - Related articles - All 2 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
